Futura Medical to Present Data on MED2005 at SMSNA
Futura Medical to Present Data on MED2005 for the Treatment of Erectile Dysfunction at the 20th Annual Fall Scientific Meeting of SMSNA and Host Advisory Meeting
15 October 2019
Futura Medical plc (AIM: FUM) (the "Company"), a pharmaceutical company developing a portfolio of innovative products based on its proprietary, transdermal DermaSys® drug delivery technology and currently focused on sexual health and pain, today announces that it will be presenting data on its DermaSys® drug delivery technology and lead product MED2005, a fast-acting, topical, nitroglycerin (GTN) gel for the treatment of erectile dysfunction ("ED")' at the 20th Annual Fall Scientific Meeting of Sexual Medicine Society of North America (SMSNA), on 24-27 October 2019 at the Omni Nashville Hotel, Nashville, Tennessee USA. Futura will also host its third Scientific Advisory Meeting with high profile US Key Opinion Leaders ("KOLs") in the field of erectile dysfunction.
Erectile dysfunction disrupts the lives of at least 1 in 5 men globally1, affecting the sexual and emotional health of around 27 million men and their partners in the US alone. There has been little innovation in ED treatments for over ten years and many patients continue to suffer dissatisfaction with existing treatments especially those looking for a fast-acting treatment that can form part of sexual foreplay or those contraindicated from using existing therapies.
Tim Holland, Director of Clinical Development at Futura Medical, will be presenting a poster (#114) entitled "Ultrasound Doppler Measurements of Penile Blood Flow as a Predictor of Clinical Efficacy" on Thursday 24 October at 3:20pm CDT. The presentation will be part of the "Erectile Dysfunction Medical/Surgical Moderated Posters" session held in the Broadway Ballroom A-B.
In addition, Futura will present cumulative safety data for MED2005 in an oral presentation (#031) entitled "Establishing the safety profile in sexual partners of a new topical nitroglycerin gel for the treatment of erectile dysfunction" on Saturday 26 October at 4:00pm CDT. The presentation will be part of the "Emerging Treatments for ED and PD" session held in Broadway Ballroom F.
James Barder, Chief Executive Officer of Futura Medical, said: "We are very pleased to share these findings on our lead programme MED2005 with the medical community at this prestigious meeting ahead of our Phase 3 data readout at the end of the year. MED2005 has the potential to be a highly differentiated therapy, especially for mild to moderate ED. Shown to be safe and fast-acting (5-10 minutes) with a favourable side effect profile - a key differentiator to other ED products on the market, which has seen very little innovation over the past ten years.
"We also look forward to hosting our third Advisory Board Panel meeting with eminent US Key Opinion Leaders in the field of erectile dysfunction and discussing this meaningful data and the on-going development and educational programme for MED2005."
For further information please contact:
Futura Medical plc
James Barder, Chief Executive
Angela Hildreth, Finance Director and COO
Email: [email protected]
Tel: +44 (0) 1483 685 670
For media enquiries please contact:
Optimum Strategic Communications
Mary Clark/ Eva Haas/ Hollie Vile
Email: [email protected]
Tel: +44 (0) 203 950 9144
Notes to editors:
About Futura Medical plc
About Futura Medical plc
Futura Medical plc (AIM: FUM), is a pharmaceutical company developing a portfolio of innovative products based on its proprietary, transdermal Dermasys® drug delivery technology. These products are optimised for clinical efficacy, safety, administration and patient convenience and are developed for the prescription and consumer healthcare markets as appropriate. Current therapeutic areas are sexual health, including erectile dysfunction, and pain relief. Development and commercialisation strategies are designed to maximise product differentiation and value creation whilst minimising risk.
The first European Phase 3 study for MED2005, referred to as "FM57", is a 1,000 patient, dose-ranging, multi-centre, randomised, double blind, placebo-controlled, home use, parallel group study of MED2005 0.2%, 0.4% and 0.6% Glyceryl Trinitrate for the treatment of erectile dysfunction with an open label extension. FM57 is progressing on track, with headline data expected by the end of 2019.
Futura is based in Guildford, Surrey, and its shares trade on the AIM market of the London Stock Exchange. www.futuramedical.com
About MED2005: Eroxon® - Topical treatment for erectile dysfunction (ED)
MED2005, which uses Futura's DermaSys® drug delivery system, is the development name for its topical glyceryl trinitrate ("GTN") gel. It has the potential to be a highly differentiated therapy for the treatment of men with ED, especially mild to moderate ED. MED2005's rapid onset of action means that it has the potential to become the world's fastest-acting treatment for ED, with a speed of onset of around five minutes. Viagra® and Cialis® which dominate the existing on-market ED therapies are taken orally and do not take effect for at least 30 minutes and typically one hour or more2. Speed of onset and method of administration of MED2005 also help restore spontaneity and intimacy. Importantly, MED2005 may also be appropriate for ED sufferers on nitrates and other drugs that are contraindicated for use with phosphodiesterase-5-inhibitors ("PDE5Is") such as Viagra® and Cialis® and other existing oral ED treatments.
1. EMEA, Withdrawal assessment report for Viagra, 2008
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
Quick facts: Futura Medical PLC
Market Cap: £62.11 m
NO INVESTMENT ADVICE
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...FOR OUR FULL DISCLAIMER CLICK HERE